Leonard Cancer Institute Earns Accreditation from the National Accreditation Program for Rectal Cancer of the American College of Surgeons

Providence News Team

Providence Mission Hospital and the Judi and Bill Leonard Cancer Institute for Prevention, Treatment and Wellness recently earned a three-year accreditation from the National Accreditation Program for Rectal Cancer (NAPRC), a quality program of the American College of Surgeons.

Providence Mission Hospital is one of only seven hospitals in California to earn this prestigious recognition and among only 75 hospitals in the U.S.

To achieve accreditation, Providence Mission Hospital demonstrated compliance with NAPRC standards for program management, quality improvement for patients, and clinical services, including advanced imaging for cancer staging. The hospital also exhibited a collaborative, multidisciplinary approach from a team of physicians and caregivers in surgery, pathology, radiology, radiation oncology and medical oncology.

Accreditation by the NAPRC is granted only to those programs that are committed to providing the best possible care to patients with rectal cancer. The NAPRC provides the structure and resources to develop and operate a high-quality rectal center, and accredited programs follow a model for organizing and managing a rectal center to ensure multidisciplinary, integrated, comprehensive rectal cancer services.

“It’s an honor to be recognized for the exceptional care we deliver to our community,” shares Dr. Matthew Brady FACS, FASCRS, Director of the Colon and Rectal Surgery Program and Rectal Cancer Program Director at Providence Mission Hospital and the Leonard Cancer Institute. “This NAPRC accreditation is a designation few hospitals in the country have achieved and highlights the commitment of our outstanding multidisciplinary team to ensuring the highest quality care for patients with rectal cancer.”

“We are blessed to have a passionate team of physicians and caregivers,” adds Chief Executive Seth Teigen. “Our Mission family is dedicated to guiding our patients on their path to healing through precision medicine and personalized care.”

To learn more about Providence Mission Hospital, click here.

About the Author

The Providence News Team brings you the updates to keep you informed about what's happening across the organizational ecosystem. From partnerships to new doctor announcements, we are committed to keeping you informed.
More Content by Providence News Team

Welcome to your journey for creating a healthier you

Leonard Cancer Institute Earns Accreditation from the National Accreditation Program for Rectal Cancer of the American College of Surgeons

About the Author

Previous Article

Next Article

Leonard Cancer Institute Earns Accreditation from the National Accreditation Program for Rectal Cancer of the American College of Surgeons

About the Author

Previous Article

Next Article

Other content in this Stream

Real-world data from Providence, Illumina and Microsoft Research finds cancer patients with early genomic testing received better precision treatment, underlines urgency to become standard practice

R. Bryan Bell, M.D., D.D.S., FACS, FRCS(Ed) has accepted the roles of executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute.

The annual SITC meeting brings together cancer immunotherapy researchers with a goal to advance science, discover breakthroughs and educate the world on cancer immunotherapy.

New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.

Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.

Providence Cancer Institute in partnership with AIM at Melanoma present a free online event designed to educate and empower patients and care partners affected by melanoma.

A new study approach reflects a deeper understanding of cancer at the molecular level and marks a shift away from one-size-fits-all treatments.

Dr. Allie Grossmann’s new lab at Earle A. Chiles Research Institute is focused on understanding how tumors communicate with their environment, grow, survive and spread.

Dr. Walter Urba, a pioneer and key figure in the development of immunotherapy, will retire from Providence Cancer Institute at the end of year.

Prominent cancer scientist Dr. Bernard Fox recognized for his work to advance the field of cancer immunotherapy through increasing public understanding, awareness and research efforts.

A new medication may help people with KRAS G12C-mutant non-small cell lung cancer. Read about the study and a trial evaluating an immunotherapy for treating head and neck squamous cell carcinoma.

Cancer survivor Mark Williams chats with Dr. Brendan Curti about

What motivates the co-captains of the FINISHCANCER caregiver team to commit their time to running this remarkable relay? Read what they say about preparing for the race and what inspires them to run.

Although chemotherapy is the cornerstone treatment for triple negative breast cancer, survival outcomes remain disappointing. Two studies could help improve treatment options.

A study designed to treat recurrent epithelial ovarian cancer looks at an antibody drug conjugate, and a second study for people with advanced breast cancer evaluates a drug that degrades estrogen rec

Providence Cancer Institute chief medical officer Walter J. Urba, M.D., Ph.D. talks about the evolution of immunotherapy in the past three decades and his vision for its future.

June is National Cancer Survivor Month, but we honor people with cancer, no matter where they are on their journey, every day of the year. Find out about the survivorship program at Providence Cancer

Providence Cancer Institute presented a free virtual education event about MRI-guided radiation therapy and how it is used to treat pancreatic cancer.

The annual meeting of cancer experts is a platform to collaborate and accelerate cancer research findings into clinical applications.

A joint study between Providence, Microsoft and the University of Washington detailing work to create a novel AI-powered pathology model has been published in Nature.